Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Kristian Shearsby
Kristian Shearsby
Special Counsel
London +44 20 7067 2394 kshearsby@cov.com Download V-card

Kristian Shearsby is special counsel in the corporate practice group in the London office.

Mr. Shearsby advises on a wide range of matters, including mergers and acquisitions, private financings and public offerings.  He has particular expertise in advising on deals in the life sciences, technology, media and mining industries.

  • Oxford BioMedica plc, a London Stock Exchange listed biopharmaceutical company, in a $55 million secured debt facility with Oaktree Capital Management - Strategic Credit Strategy.
  • Advising a joint venture vehicle owned by a bureau of the Chinese government and a London based AIM listed mining company on the acquisition of Namibian mining assets, a fundraising and admission to trading on AIM.
  • Advising Advent Venture Partners and others on the sale of visual effects software company, The Foundry, to The Carlyle Group.
  • Advising a London based AIM listed mining company in relation to the acquisition of significant African mining operations, constituting a reverse takeover and re-admission to AIM and subsequent transactional matters including a placing in November 2010.
  • Advising On Demand Group, a subsidiary of NASDAQ listed SeaChange International, on the acquisition of Mobix Interactive.
  • Advising Thiakis Limited, a privately held UK biotechnology company and its shareholders, on its acquisition by Wyeth.
  • Advising the institutional and individual owners of PIramed, a privately owned UK company focusing on treatments for cancer and immune inflammatory diseases, on the sale of the company to Roche.
  • Advising technology venture fund, DFJ Esprit and the other selling shareholders, on the sale of portfolio company Buy.at to AOL.